Literature DB >> 12044972

Stimulation of chemokine CXC receptor 4 induces synaptic depression of evoked parallel fibers inputs onto Purkinje neurons in mouse cerebellum.

Davide Ragozzino1, Massimiliano Renzi, Aldo Giovannelli, Fabrizio Eusebi.   

Abstract

In the present work, we studied the effects of the stimulation of the chemokine CXC receptor 4 (CXCR4) by the stromal-derived cell growth factor-1alpha (SDF-1alpha) on the evoked excitatory postsynaptic current. This was generated in Purkinje neurons (PN) from mouse cerebellar slices by the stimulation of parallel fibers. It was found that the amplitude of EPSC was reversibly reduced by SDF-1alpha application. This effect was dose-dependent (IC(50)=0.34 nM) and was abolished by the anti-CXCR4 monoclonal antibody (mAb) 12G5. This SDF-1alpha-induced synaptic depression was caused by a decrease of evoked glutamate release, rather than a decrease in the postsynaptic glutamate receptor (GluR) sensitivity, as the mean amplitude of the spontaneous EPSCs was not influenced by chemokine application. Moreover, NMDA receptors (NMDARs) are involved in EPSC depression being inhibited by the NMDAR blocker 2-amino-5-phosphonopentanoic acid (AP-5). The mechanisms by which SDF-1alpha modulates neurotransmission in the cerebellar cortex are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044972     DOI: 10.1016/s0165-5728(02)00093-0

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  16 in total

Review 1.  CXC chemokine receptors in the central nervous system: Role in cerebellar neuromodulation and development.

Authors:  Davide Ragozzino
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey.

Authors:  Silke Heinisch; Jonathan Palma; Lynn G Kirby
Journal:  Brain Behav Immun       Date:  2010-10-23       Impact factor: 7.217

3.  Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors:  R Pattarini; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2007-01-29       Impact factor: 3.590

Review 4.  Neuronal chemokines: versatile messengers in central nervous system cell interaction.

Authors:  A H de Haas; H R J van Weering; E K de Jong; H W G M Boddeke; K P H Biber
Journal:  Mol Neurobiol       Date:  2007-07-10       Impact factor: 5.590

Review 5.  Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology.

Authors:  Meizhang Li; Richard M Ransohoff
Journal:  Prog Neurobiol       Date:  2007-11-26       Impact factor: 11.685

Review 6.  Functional diversity of SDF-1 splicing variants.

Authors:  Miroslaw Janowski
Journal:  Cell Adh Migr       Date:  2009-07-23       Impact factor: 3.405

7.  Exploring the genomic basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene expression profiling studies on brain tissue from epilepsy surgery.

Authors:  Nasir Mirza; Olga Vasieva; Anthony Guy Marson; Munir Pirmohamed
Journal:  Hum Mol Genet       Date:  2011-08-18       Impact factor: 6.150

8.  Chemokine fractalkine/CX3CL1 negatively modulates active glutamatergic synapses in rat hippocampal neurons.

Authors:  Davide Ragozzino; Silvia Di Angelantonio; Flavia Trettel; Cristina Bertollini; Laura Maggi; Cornelius Gross; Israel F Charo; Cristina Limatola; Fabrizio Eusebi
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

Review 9.  Viewing chemokines as a third major system of communication in the brain.

Authors:  Martin W Adler; Ellen B Geller; Xiaohong Chen; Thomas J Rogers
Journal:  AAPS J       Date:  2006-01-06       Impact factor: 4.009

10.  SDF-1alpha/CXCL12 enhances GABA and glutamate synaptic activity at serotonin neurons in the rat dorsal raphe nucleus.

Authors:  Silke Heinisch; Lynn G Kirby
Journal:  Neuropharmacology       Date:  2009-09-13       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.